Giant cell tumor of bone (GCTB) is characterized by uncertain biological behavior due to its local aggressiveness and metastasizing potential. In this study, we conducted a meta-analysis of the contemporary literature to evaluate all management strategies for GCTB metastases. A combination of the terms “lung metastases”, “giant cell tumor”, “bone”, “treatment”, and “oncologic outcomes” returned 133 patients meeting our inclusion criteria: 64 males and 69 females, with a median age of 28 years (7–63), at the onset of primary GCTB. Lung metastases typically occur at a mean interval of 26 months (range: 0–143 months) after treatment of the primary site, commonly presenting as multiple and bilateral lesions. Various treatment approaches, including surgery, chemotherapy, radiotherapy, and drug administration, were employed, while 35 patients underwent routine monitoring only. Upon a mean follow-up of about 7 years (range: 1–32 years), 90% of patients were found to be alive, while 10% had died. Death occurred in 25% of patients who had chemotherapy, whereas 96% of those not treated or treated with Denosumab alone were alive at a mean follow-up of 6 years (range: 1–19 years). Given the typically favorable prognosis of lung metastases in patients with GCTB, additional interventions beyond a histological diagnosis confirmation may not be needed. Denosumab, by reducing the progression of the disease, can play a pivotal role in averting or delaying lung failure.

中文翻译：

---

狄诺塞麦时代骨巨细胞瘤患者肺转移的评估与治疗

骨巨细胞瘤（GCTB）因其局部侵袭性和转移潜力而具有不确定的生物学行为。在这项研究中，我们对当代文献进行了荟萃分析，以评估 GCTB 转移的所有治疗策略。 “肺转移”、“巨细胞瘤”、“骨”、“治疗”和“肿瘤结果”等术语的组合返回了 133 名符合我们纳入标准的患者：64 名男性和 69 名女性，中位年龄为 28 岁(7-63)，在原发性 GCTB 开始时。肺转移通常在原发部位治疗后平均间隔 26 个月（范围：0-143 个月）发生，通常表现为多发性和双侧病变。采取了手术、化疗、放疗、药物等多种治疗方法，35例患者仅进行常规监测。经过平均约 7 年（范围：1-32 年）的随访，发现 90% 的患者还活着，而 10% 的患者已经死亡。接受化疗的患者中有 25% 死亡，而未接受治疗或仅接受狄诺塞麦治疗的患者中，96% 在平均随访 6 年（范围：1-19 年）时仍存活。鉴于 GCTB 患者肺转移的预后通常良好，除了组织学诊断确认之外，可能不需要额外的干预措施。狄诺塞麦通过减少疾病的进展，可以在避免或延缓肺衰竭方面发挥关键作用。